Radius Health to Present at the 34th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Dec. 22, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including metastatic breast cancer, today announced that President and Chief Executive Officer, Robert E. Ward, will present at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2016 at 8:30 a.m. PST at the Westin St. Francis Hotel in San Francisco.
The Company's presentation will be webcast live on the Company's website at www.radiuspharm.com, and a replay of the presentation will be available on the Company's website following the presentation.
About Radius Health
Radius is a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers. Radius' lead development candidate is the investigational drug abaloparatide for subcutaneous injection, currently in Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone driven, or hormone resistant, metastatic breast cancer, and vasomotor symptoms. www.radiuspharm.com
CONTACT: Investor Relations Barbara Ryan Partner Clermont Partners 203-274-2825 bryan@radiuspharm.com Media Alice Pomponio V.P. Corporate Affairs 508-215-9846 apomponio@radiuspharm.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
